Emerging injectable therapies for osteoarthritis

References

• The Pre-Competitive Consortium for Osteoarthritis (Osteoarthritis Research Society International). OARSI “white paper” - osteoarthritis: a serious disease. [Internet]. 2016 cited 2021 Mar 21]. Available from 2021 Mar 21: https://oarsi.org/education/oarsi-resources/oarsi-white-paper-oa-serious-disease
   Google Scholar
• Swain S, Sarmanova A, Coupland C, et al. Comorbidities in osteoarthritis: a systematic review and meta-analysis of observational studies. Arthritis Care Res. 2020;72(7):991–1000.
   Web of Science ®Google Scholar
• Marshall DA, Liu X, Barnabe C, et al. Existing comorbidities in people with osteoarthritis: a retrospective analysis of a population-based cohort in Alberta, Canada. BMJ Open. 2019 Nov 1 9(11):e033334.
   PubMed Web of Science ®Google Scholar
• Veronese N, Cereda E, Maggi S, et al. Osteoarthritis and mortality: a prospective cohort study and systematic review with meta-analysis. Semin Arthritis Rheum. 2016 Oct;46(2):160–167.
   PubMed Web of Science ®Google Scholar
• Wilkie R, Parmar SS, Blagojevic-Bucknall M, et al. Reasons why osteoarthritis predicts mortality: path analysis within a Cox proportional hazards model. RMD Open. 2019 Nov 1 5(2):e001048.
   PubMed Web of Science ®Google Scholar
• American Academy of Orthopaedic Surgeons management of osteoarthritis of the knee (nonarthroplasty) evidence-based clinical practice guideline. [Internet]. 2021. [cited 2022 April 26]. Available from: https://www.aaos.org/oak3cpg
   Google Scholar
• VA/DoD clinical practice guidelines (2020) The Non-Surgical Management of Hip & Knee Osteoarthritis (OA) [Internet]. [cited 2022 Apr 26]. Available from 2022 Apr 26: https://www.healthquality.va.gov/guidelines/cd/oa/index.asp
   Google Scholar
• Kolasinski SL, Neogi T, Hochberg MC, et al. American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 2019 [2020 Feb];72(2):220–233.
   Web of Science ®Google Scholar
• Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Nov 1 27(11):1578–1589.
   PubMed Web of Science ®Google Scholar
• An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) | Elsevier Enhanced Reader [Internet]. cited 2022 Apr 26]. Available from 2022 Apr 26: https://reader.elsevier.com/reader/sd/pii/S0049017219300435?token=CC9DFEE2B7073B732A0763666BE86015AA7261E7FD1C0DD813FFFF0EE193091C1AE38AD079005CE1F16ED406438183E5&originRegion=us-east-1&originCreation=20220424214844
   Google Scholar
• Zhang Z, Huang C, Jiang Q, et al. Guidelines for the diagnosis and treatment of osteoarthritis in China (2019 edition). Ann Transl Med. 2020 Oct;8(19):1213.
   PubMed Web of Science ®Google Scholar
• RACGP - Guideline for the management of knee and Hip osteoarthritis [Internet]. cited 2022 Apr 26]. Available from 2022 Apr 26: https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/knee-and-hip-osteoarthritis
   Google Scholar
• Rillo O, Riera H, Acosta C, et al. PANLAR consensus recommendations for the management in osteoarthritis of hand, hip, and knee. JCR: J Clinic Rheumatol. 2016 Oct;22(7):345–354.
   PubMed Web of Science ®Google Scholar
• Evidence | osteoarthritis: care and management | guidance | NICE [Internet]. NICE; cited 2022 Apr 26]. Available from 2022 Apr 26: https://www.nice.org.uk/guidance/cg177/evidence
   Google Scholar
• Clinical Practice Guidelines | Malaysian Society of Rheumatology [Internet]. cited 2022 Apr 26]. Available from 2022 Apr 26: https://msr.my/resources/cpg/
   Google Scholar
• Fernandes L, Hagen KB, Bijlsma JWJ, et al. EULAR recommendations for the non-pharmacological core management of Hip and knee osteoarthritis. Ann Rheum Dis. 2013 Jul;72(7):1125–1135.
   PubMed Web of Science ®Google Scholar
• Kloppenburg M, Kroon FP, Blanco FJ, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019 Jan 1 78(1):16–24.
   PubMed Web of Science ®Google Scholar
• Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2000 Dec 1 59(12):936–944.
   PubMed Web of Science ®Google Scholar
• Martel-Pelletier J, Barr AJ, Cicuttini FM, et al. Osteoarthritis. Nat Rev Dis Primers. 2016 Oct 13;2(1):16072.
   PubMed Web of Science ®Google Scholar
• Mobasheri A, Batt M. An update on the pathophysiology of osteoarthritis. Ann Phys Rehabil Med. 2016 Dec;59(5–6):333–339.
   PubMed Web of Science ®Google Scholar
• Laday J Osteoarthritis drug pipeline rattles as FDA rejects top contender: what comes next? [Internet]. cited 2022 Apr 18]. Available from 2022 Apr 18: https://www.healio.com/news/rheumatology/20210428/osteoarthritis-drug-pipeline-rattles-as-fda-rejects-top-contender-what-comes-next
   Google Scholar
• CFR - Code of Federal Regulations Title 21 [Internet]. cited 2022 Apr 26]. Available from 2022 Apr 26: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.300
   Google Scholar
• Ackerman IN, Bohensky MA, Zomer E, et al. The projected burden of primary total knee and Hip replacement for osteoarthritis in Australia to the year 2030. BMC Musculoskelet Disord. 2019 Feb 23 20(1):90.
   PubMedGoogle Scholar
• Mandl LA. Determining who should be referred for total Hip and knee replacements. Nat Rev Rheumatol. 2013 Jun;9(6):351–357.
   PubMed Web of Science ®Google Scholar
• Zeng C, Doherty M, Persson MSM, et al. Comparative efficacy and safety of Acetaminophen, topical and oral non-steroidal anti-inflammatory drugs for knee osteoarthritis: evidence from a network meta-analysis of randomized controlled trials and real-world data. Osteoarthritis Cartilage. 2021 Sep;29(9):1242–1251.
   PubMed Web of Science ®Google Scholar
• Leopoldino AO, Machado GC, Ferreira PH, et al. Paracetamol versus placebo for knee and Hip osteoarthritis. Cochrane Database Syst Rev. 2019 Feb 25;2:CD013273.
   PubMedGoogle Scholar
• Kaye K Trouble with tramadol. cited 2022 Apr 26]; Available from 2022 Apr 26: https://www.nps.org.au/australian-prescriber/articles/trouble-with-tramadol
   Google Scholar
• Paskins Z, Bromley K, Lewis M , et al. Clinical effectiveness of one ultrasound guided intra-articular corticosteroid and local anaesthetic injection in addition to advice and education for Hip osteoarthritis (HIT trial): single blind, parallel group, three arm, randomised controlled trial. BMJ. 2022. doi:10.1136/bmj-2021-068446.
   PubMedGoogle Scholar
• Progression of Knee Osteoarthritis With Use of Intraarticular Glucocorticoids Versus Hyaluronic Acid. cited 2022 Apr 26]; Available from 2022 Apr 26: https://onlinelibrary.wiley.com/doi/10.1002/art.42031
   Google Scholar
• Zhu Y, Yuan M, Meng HY, et al. Basic science and clinical application of platelet-rich plasma for cartilage defects and osteoarthritis: a review. Osteoarthritis Cartilage. 2013 Nov;21(11):1627–1637.
   PubMed Web of Science ®Google Scholar
• Moussa M, Lajeunesse D, Hilal G, et al. Platelet rich plasma (PRP) induces chondroprotection via increasing autophagy, anti-inflammatory markers, and decreasing apoptosis in human osteoarthritic cartilage. Exp Cell Res. 2017 Mar 1 352(1):146–156.
   PubMed Web of Science ®Google Scholar
• Gato-Calvo L, Magalhaes J, Ruiz-Romero C, et al. Platelet-rich plasma in osteoarthritis treatment: review of current evidence. Ther Adv Chronic Dis. 2019 Feb 19; 10:2040622319825567
   Web of Science ®Google Scholar
• Migliorini F, Driessen A, Quack V, et al. Comparison between intra-articular infiltrations of placebo, steroids, hyaluronic and PRP for knee osteoarthritis: a Bayesian network meta-analysis. Arch Orthop Trauma Surg. [2021 Sep 1];141(9):1473–1490.
   PubMed Web of Science ®Google Scholar
• Bennell KL, Paterson KL, Metcalf BR, et al. Effect of intra-articular platelet-rich plasma vs placebo injection on pain and medial tibial cartilage volume in patients with knee osteoarthritis: the RESTORE randomized clinical trial. JAMA. 2021 Nov 23 326(20):2021–2030.
   PubMed Web of Science ®Google Scholar
• Dório M, Pereira RMR, Luz AGB, et al. Efficacy of platelet-rich plasma and plasma for symptomatic treatment of knee osteoarthritis: a double-blinded placebo-controlled randomized clinical trial. BMC Musculoskelet Disord. 2021 Dec;22(1):822.
   PubMedGoogle Scholar
• Paget LDA, Reurink G, de Vos RJ, et al. Effect of platelet-rich plasma injections vs placebo on ankle symptoms and function in patients with ankle osteoarthritis: a randomized clinical trial. JAMA. 2021 Oct 26 326(16):1595–1605.
   PubMed Web of Science ®Google Scholar
• Barker PA, Mantyh P, Arendt-Nielsen L, et al. Nerve growth factor signaling and its contribution to pain. J Pain Res. 2020 May 26;13:1223–1241.
   PubMed Web of Science ®Google Scholar
• Wise BL, Seidel MF, Lane NE. The evolution of nerve growth factor inhibition in clinical medicine. Nat Rev Rheumatol. 2021 Jan;17(1):34–46.
   PubMed Web of Science ®Google Scholar
• Campbell JN, Stevens R, Hanson P, et al. Injectable capsaicin for the management of pain due to osteoarthritis. Molecules. 2021 Feb 3 26(4):778.
   PubMed Web of Science ®Google Scholar
• Ghouri A, Quicke JG, Conaghan PG. New developments in osteoarthritis pharmacological therapies. Rheumatology (Oxford). 2021 Dec 24; 60(Suppl 6):vi1–11.
   PubMedGoogle Scholar
• Lories RJ, Monteagudo S. Review article: is wnt signaling an attractive target for the treatment of osteoarthritis? Rheumatol Ther. 2020 Apr 10;7(2):259–270.
   PubMed Web of Science ®Google Scholar
• Gigout A, Guehring H, Froemel D, et al. Sprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix. Osteoarthritis Cartilage. 2017 Nov;25(11):1858–1867.
   PubMed Web of Science ®Google Scholar
• Vincent TL. IL-1 in osteoarthritis: time for a critical review of the literature. F1000Res. 2019 Jun 21;8:F1000. Faculty Rev-934.
   PubMedGoogle Scholar
• Kraus VB, Birmingham J, Stabler TV, et al. Effects of intraarticular IL1-Ra for acute anterior cruciate ligament knee injury: a randomized controlled pilot trial (NCT00332254). Osteoarthritis Cartilage. 2012 Apr 1 20(4):271–278.
   PubMed Web of Science ®Google Scholar
• Brown C, Toth A, Magnussen R. Clinical benefits of intra-articular anakinra for persistent knee effusion. J Knee Surg. 2011 Mar;24(1):061.
   PubMedGoogle Scholar
• Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2009 Mar 15 61(3):344–352.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Proudman S, Kivitz AJ, et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res Ther. 2011 Jul 29 13(4):R125.
   PubMed Web of Science ®Google Scholar
• Kloppenburg M, Peterfy C, Haugen IK, et al. Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Ann Rheum Dis. 2019 Mar 1 78(3):413–420.
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Bliddal H, Blanco FJ, et al. A phase ii trial of lutikizumab, an anti–interleukin-1α/β dual variable domain immunoglobulin, in knee osteoarthritis patients with synovitis. Arthritis Rheumatol. 2019;71(7):1056–1069.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017 Sep 21 377(12):1119–1131.
   PubMed Web of Science ®Google Scholar
• Schieker M, Conaghan PG, Mindeholm L, et al. Effects of interleukin-1β inhibition on incident hip and knee replacement : exploratory analyses from a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2020 Oct 6;173(7):509–515.
   PubMed Web of Science ®Google Scholar
• Altomare A, Corrado A, Maruotti N, et al. The role of Interleukin-1 receptor antagonist as a treatment option in calcium pyrophosphate crystal deposition disease. Mol Biol Rep. 2021;48(5):4789–4796.
   PubMed Web of Science ®Google Scholar
• So A, Dumusc A, Nasi S. The role of IL-1 in gout: from bench to bedside. Rheumatology. 2018 Jan 1;57(suppl_1):i12–9.
   PubMedGoogle Scholar
• McCarthy GM, Dunne A. Calcium crystal deposition diseases — beyond gout. Nat Rev Rheumatol. 2018;14(10):592–602.
   PubMed Web of Science ®Google Scholar
• Bykerk VP. The efficacy and safety of targeting GM-CSF in arthritis. Lancet Rheumatol. 2020 Nov;2(11):e648–50.
   PubMedGoogle Scholar
• Buckley C, Simon JA, Zhdan V, et al. Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study. Lancet Rheumatol. 2020 Nov 1 2(11):e677–88.
   Google Scholar
• Genovese MC, Berkowitz M, Conaghan PG, et al. MRI of the joint and evaluation of the granulocyte–macrophage colony-stimulating factor–CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study. Lancet Rheumatol. 2020 Nov;2(11):e666–76.
   Google Scholar
• Schett G, Bainbridge C, Berkowitz M, et al. Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial. Lancet Rheumatol. 2020 Oct 1 2(10):e623–32.
   Google Scholar
• Chisari E, Yaghmour KM, Khan WS. The effects of TNF-alpha inhibition on cartilage: a systematic review of preclinical studies. Osteoarthr Cartil. 2020 May;28(5):708.
   PubMed Web of Science ®Google Scholar
• Kloppenburg M, Ramonda R, Bobacz K, et al. Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018 Dec;77(12):1757–1764.
   PubMed Web of Science ®Google Scholar
• Chevalier X, Ravaud P, Maheu E, et al. Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis. 2015 Sep;74(9):1697–1705.
   PubMed Web of Science ®Google Scholar
• Aitken D, Laslett LL, Pan F, et al. A randomised double-blind placebo-controlled crossover trial of HUMira (Adalimumab) for erosive hand OsteoaRthritis - the HUMOR trial. Osteoarthritis Cartilage. 2018 Jul;26(7):880–887.
   PubMed Web of Science ®Google Scholar
• Richette P, Latourte A, Sellam J, et al. Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial. Ann Rheum Dis. 2021 Mar 1 80(3):349–355.
   PubMed Web of Science ®Google Scholar
• Ohtori S, Orita S, Yamauchi K, et al. Efficacy of direct injection of etanercept into knee joints for pain in moderate and severe knee osteoarthritis. Yonsei Med J. 2015 Sep;56(5):1379–1383.
   PubMed Web of Science ®Google Scholar
• Wang J. Efficacy and safety of Adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: an open-label randomized controlled trial. J Int Med Res. 2018 Jan;46(1):326–334.
   PubMed Web of Science ®Google Scholar
• Food And Drug Administration. FDA Briefing Document: Joint Meeting of Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee. . [Internet]. 2021. [cited 2022 April 26]. Available from: https://www.fda.gov/media/146867/download
   Google Scholar
• Hu R, Song YF, Yang ZY, et al. Clinical outcomes of tanezumab with different dosages for patient with osteoarthritis: network meta-analysis. Front Pharmacol. 2021 Jun 11; 12:614753
   PubMed Web of Science ®Google Scholar
• Fan ZR, Ma JX, Wang Y, et al. Efficacy and safety of tanezumab administered as a fixed dosing regimen in patients with knee or Hip osteoarthritis: a meta-analysis of randomized controlled phase III trials. Clin Rheumatol. 2021 Jun;40(6):2155–2165.
   PubMed Web of Science ®Google Scholar
• Tive L, Bello AE, Radin D, et al. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or Hip. J Pain Res. 2019 Mar 19;12:975–995.
   PubMed Web of Science ®Google Scholar
• Kan SL, Li Y, Ning GZ, et al. Tanezumab for patients with osteoarthritis of the knee: a meta-analysis. PLOS ONE. 2016 Jun 13 11(6):e0157105.
   PubMed Web of Science ®Google Scholar
• Chen J, Li J, Li R, et al. Efficacy and safety of tanezumab on osteoarthritis knee and hip pains: a meta-analysis of randomized controlled trials. Pain Med. 2017 Feb 1 18(2):374–385.
   PubMed Web of Science ®Google Scholar
• Sanga P, Katz N, Polverejan E, et al. Long-term safety and efficacy of fulranumab in patients with moderate-to-severe osteoarthritis pain: a phase ii randomized, double-blind, placebo-controlled extension study. Arthritis Rheumatol. 2017 Apr;69(4):763–773.
   PubMed Web of Science ®Google Scholar
• Cai X, Yuan S, Zeng Y, et al. Frontiers | new trends in pharmacological treatments for osteoarthritis | pharmacology [internet]. New Trends in Pharmacological Treatments for Osteoarthritis. 2021 cited 2022 Apr 24]. Available from 2022 Apr 24: https://www.frontiersin.org/articles/10.3389/fphar.2021.645842/full
   Google Scholar
• Bothwell M. Recent advances in understanding neurotrophin signaling. F1000Res. 2016;5:F1000. Faculty Rev-1885.
   PubMedGoogle Scholar
• Dakin P, DiMartino SJ, Gao H, et al. The efficacy, tolerability, and joint safety of fasinumab in osteoarthritis pain: a phase iib/iii double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheumatol. 2019 Nov;71(11):1824–1834.
   PubMed Web of Science ®Google Scholar
• Krupka E, Jiang GL, Jan C. Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study. Osteoarthritis Cartilage. 2019 Nov;27(11):1599–1607.
   PubMed Web of Science ®Google Scholar
• Ishiguro N, Oyama S, Higashi R, et al. Efficacy, safety, and tolerability of ONO-4474, an orally available pan-tropomyosin receptor kinase inhibitor, in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, placebo-controlled, double-blind, parallel-group comparative study. J Clin Pharmacol. 2020 Jan;60(1):28–36.
   PubMed Web of Science ®Google Scholar
• Watt FE, Blauwet MB, Fakhoury A, et al. Tropomyosin-related kinase A (TrkA) inhibition for the treatment of painful knee osteoarthritis: results from a randomized controlled phase 2a trial. Osteoarthritis Cartilage. 2019 Nov;27(11):1590–1598.
   PubMed Web of Science ®Google Scholar
• Stevens RM, Ervin J, Nezzer J, et al. Randomized, double-blind, placebo-controlled trial of intraarticular trans-capsaicin for pain associated with osteoarthritis of the knee. Arthritis Rheumatol. 2019 Sep;71(9):1524–1533.
   PubMed Web of Science ®Google Scholar
• Stevens R, Hanson P, Tiseo P, et al. Op0187 determining optimal cooling and administration methods for cntx-4975 intra-articular injection in subjects with moderate to severe osteoarthritis knee pain. Ann Rheum Dis. 2020 Jun 1 79(Suppl 1):116.
   Google Scholar
• Centrexion Therapeutics. A randomized, double-blind, placebo-controlled, 2-injection, 52-week study to evaluate the efficacy and safety of intra-articular injections of CNTX-4975-05 in subjects with chronic, moderate-to-severe osteoarthritis knee pain [internet]. clinicaltrials.gov; 2021 Jun [cited 2022 Apr 21]. Report No.: NCT03660943. Available from: https://clinicaltrials.gov/ct2/show/NCT03660943
   Google Scholar
• Leiman D, Minkowitz H, Levitt RC, et al. Preliminary results from a phase 1b double-blind study to assess the safety, tolerability and efficacy of intra-articular administration of resiniferatoxin or placebo for the treatment of moderate to severe pain due to osteoarthritis of the knee. Osteoarthritis Cartilage. 2020 Apr 1;28:S138.
   Web of Science ®Google Scholar
• Yazici Y, McAlindon TE, Fleischmann R, et al. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthritis Cartilage. 2017 Oct 1 25(10):1598–1606.
   PubMed Web of Science ®Google Scholar
• Yazici Y, McAlindon TE, Gibofsky A, et al. Lorecivivint, a novel intraarticular CDC-like kinase 2 and dual-specificity tyrosine phosphorylation-regulated kinase 1a inhibitor and wnt pathway modulator for the treatment of knee osteoarthritis: a phase ii randomized trial. Arthritis Rheumatol. 2020;72(10):1694–1706.
   PubMed Web of Science ®Google Scholar
• Yazici Y, McAlindon TE, Gibofsky A, et al. A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis. Osteoarthritis Cartilage. 2021 May;29(5):654–666.
   PubMed Web of Science ®Google Scholar
• Biosplice Therapeutics, Inc. A phase 3, 28-week, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single injection of sm04690 injected in the target knee joint of moderately to severely symptomatic osteoarthritis subjects [internet]. clinicaltrials.gov; 2022 Mar [cited 2022 Apr 14]. Report No.: NCT04385303. Available from: https://clinicaltrials.gov/ct2/show/NCT04385303
   Google Scholar
• Biosplice Therapeutics, Inc. A phase 3, 56-week, multicenter, randomized, double-blind, placebo-controlled study utilizing patient-reported and radiographic outcomes to evaluate the efficacy and safety of a single injection of SM04690 injected in the target knee joint of moderately to severely symptomatic osteoarthritis subjects [internet]. clinicaltrials.gov; 2021 Oct [cited 2022 Apr 14]. Report No.: NCT03928184. Available from: https://clinicaltrials.gov/ct2/show/NCT03928184
   Google Scholar
• Biosplice Therapeutics, Inc. A long-term extension study evaluating the safety and efficacy of lorecivivint in subjects with osteoarthritis of the knee [internet]. ClinicalTrials.gov; 2022 Mar [cited 2022 Apr 14]. Report No.: NCT04520607. Available from: https://clinicaltrials.gov/ct2/show/NCT04520607
   Google Scholar
• Hochberg MC, Guermazi A, Guehring H, et al. Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD Randomized Clinical Trial. JAMA. 2019 Oct 8 322(14):1360–1370.
   PubMed Web of Science ®Google Scholar
• Eckstein F, Hochberg MC, Guehring H, et al. Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study. Ann Rheum Dis. 2021;80(8):1062–1069. May 7;annrheumdis-2020-219181.
   PubMed Web of Science ®Google Scholar
• Hayashibara T, Hiraga T, Yi B, et al. A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo. J Bone Miner Res. 2004 Mar;19(3):455–462.
   PubMed Web of Science ®Google Scholar
• McGuire D, Lane N, Segal N, et al. TPX-100 leads to marked, sustained improvements in subjects with knee osteoarthritis: pre-clinical rationale and results of a controlled clinical trial. Osteoarthritis Cartilage. 2018 Apr 1;26:S243.
   Web of Science ®Google Scholar
• McGuire D, Bowes M, Brett A, et al. Study TPX-100-5: intra-articular TPX-100 significantly delays pathological bone shape change and stabilizes cartilage in moderate to severe bilateral knee OA. Arthritis Res Ther. 2021 Sep 17 23(1):242.
   PubMed Web of Science ®Google Scholar
• Childs BG, Gluscevic M, Baker DJ, et al. Senescent cells: an emerging target for diseases of ageing. Nat Rev Drug Discov. 2017 Oct;16(10):718–735.
   PubMed Web of Science ®Google Scholar
• Hsu B, Visich J, Lane NE, et al. Safety, tolerability, pharmacokinetics, and clinical outcomes following treatment of painful knee osteoarthritis with senolytic molecule UBX0101. Osteoarthritis Cartilage. 2020 Apr 1;28:S479–80.
   Web of Science ®Google Scholar
• Lane N, Hsu B, Visich J, et al. A phase 2, randomized, double-blind, placebo-controlled study of senolytic molecule UBX0101 in the treatment of painful knee osteoarthritis. Osteoarthritis Cartilage. 2021 Apr 1; 29:S52–3
   Web of Science ®Google Scholar